P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?

Autor: Tarun Gupta, Sreedhar Subramanian, Munir Pirmohamed, Mark R. Middleton, Eve Fryer, Sarah C. Sasson, Anna Olsson-Brown, Benjamin P. Fairfax, Cheung Vtf., Elena Collantes, Joseph J. Sacco, Alison Simmons, Miranda Payne, Paul Klenerman, Jonathan Heseltine, Oliver Brain

Publikováno v: Journal of Crohn's and Colitis. 14:S286-S288

Background Immune checkpoint inhibitors (ICI) have revolutionised oncological care but cause immune-related adverse events (irAE). Inflammation of the gastrointestinal tract (enterocolitis) is the most frequent cause of significant morbidity and cess

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da9fad1f0d5447b7df8c8e0c90c9da25
https://doi.org/10.1093/ecco-jcc/jjz203.401

Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?

Autor: Miranda Payne, Mark R. Middleton, Elena Collantes, Sreedhar Subramanian, Joseph J. Sacco, Sarah C. Sasson, Jonathan Heseltine, Alison Simmons, Anna Olsson-Brown, Mark Tuthill, Cheung Vtf., Eve Fryer, Tarun Gupta, Paul Klenerman, A S Protheroe, Oliver Brain, Meenali Chitnis, Munir Pirmohamed, Benjamin P. Fairfax

Publikováno v: British Journal of Cancer

Background Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes. Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7fe15e127ac53c73fa25c05b1c06c0f
https://pubmed.ncbi.nlm.nih.gov/32418993

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Interferon-Gamma-Producing CD8 ⁺ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.

Autor: Sasson SC; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Slevin SM; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Cheung VTF; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Nassiri I; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom., Olsson-Brown A; Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; The Clatterbridge Cancer Centre National Health Service Foundation Trust, Wirral, United Kingdom., Fryer E; Department of Cellular Pathology, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Ferreira RC; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Trzupek D; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Gupta T; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom., Al-Hillawi L; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Issaias ML; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Easton A; Department of Cellular Pathology, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Campo L; Translational Histopathology Laboratory, Department of Oncology, University of Oxford, United Kingdom., FitzPatrick MEB; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Adams J; Berkshire Cancer Centre, Royal Berkshire Hospital, Reading, United Kingdom., Chitnis M; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Protheroe A; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Tuthill M; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Coupe N; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Simmons A; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom., Payne M; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Middleton MR; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Travis SPL; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Fairfax BP; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Klenerman P; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom., Brain O; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom. Electronic address: oliver.brain@ouh.nhs.uk.

Publikováno v: Gastroenterology [Gastroenterology] 2021 Oct; Vol. 161 (4), pp. 1229-1244.e9. Date of Electronic Publication: 2021 Jun 17.

Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis.

Autor: Sasson SC; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Zaunders JJ; Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia., Nahar K; Melanoma Institute Australia and The University of Sydney, Sydney, Australia., Munier CML; The Kirby Institute, University of New South Wales, Sydney, Australia., Fairfax BP; Department of Oncology, Churchill Hospital, Oxford, UK.; Department of Oncology, University of Oxford, Oxford, UK.; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Olsson-Brown A; The Clatterbridge Cancer Centre NHS Foundation Trust and Institute of Translational Medicine, University of Liverpool, Liverpool, UK., Jolly C; The Clatterbridge Cancer Centre NHS Foundation Trust and Institute of Translational Medicine, University of Liverpool, Liverpool, UK., Read SA; Westmead Institute of Medical Research, Sydney, Australia.; Western Sydney University, Sydney, Australia., Ahlenstiel G; Westmead Institute of Medical Research, Sydney, Australia.; Department of Gastroenterology, Blacktown Hospital, Sydney, Australia., Palendira U; Discipline of Infectious Diseases and Immunology, The University of Sydney, Sydney, Australia., Scolyer RA; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia., Carlino MS; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia., Payne MJ; Department of Oncology, Churchill Hospital, Oxford, UK., Cheung VTF; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Gupta T; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Klenerman P; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Peter Medawar Building of Pathogen Research, University of Oxford, Oxford, UK., Long GV; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Royal North Shore Hospital and Mater Hospitals, Sydney, Australia., Brain O; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Gastroenterology, John Radcliffe Hospital, Oxford, UK., Menzies AM; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Royal North Shore Hospital and Mater Hospitals, Sydney, Australia., Kelleher AD; Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.; The Kirby Institute, University of New South Wales, Sydney, Australia.

Publikováno v: Clinical and experimental immunology [Clin Exp Immunol] 2020 Dec; Vol. 202 (3), pp. 335-352. Date of Electronic Publication: 2020 Aug 19.